Fund manager pleads guilty to insider trading

Former FrontPoint fund manager Joseph Skowron pleaded guilty to an insider trading charge related to Human Genome Sciences' hepatitis C drug. Skowron received tips on clinical trials outcomes from hepatitis C expert and former HGS advisor Yves Benhamou that helped his fund avoid more than $30 million in losses, according to Bloomberg. Report

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.